BH3:F PTC Therapeutics Inc.

EUR 23.40 1.00 4.464286
Icon

PTC Therapeutics Inc. (BH3:F) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | F
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 23.40

+1.00 (+4.46)%

EUR 1.82B

200.00

N/A

N/A

Icon

BH3:F

PTC Therapeutics Inc. (EUR)
COMMON STOCK | F
EUR 23.40
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 1.82B

N/A

EUR 23.40

PTC Therapeutics Inc. (BH3:F) Stock Forecast

N/A

Based on the PTC Therapeutics Inc. stock forecast from 0 analysts, the average analyst target price for PTC Therapeutics Inc. is not available over the next 12 months. PTC Therapeutics Inc.’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of PTC Therapeutics Inc. is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, PTC Therapeutics Inc.’s stock price was EUR 23.40. PTC Therapeutics Inc.’s stock price has changed by -4.10% over the past week, -15.22% over the past month and -51.45% over the last year.

No recent analyst target price found for PTC Therapeutics Inc.
No recent average analyst rating found for PTC Therapeutics Inc.

Company Overview PTC Therapeutics Inc.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscula...Read More

https://www.ptcbio.com

100 Corporate Court, South Plainfield, NJ, United States, 07080

988

December

EUR

Germany

Adjusted Closing Price for PTC Therapeutics Inc. (BH3:F)

Loading...

Unadjusted Closing Price for PTC Therapeutics Inc. (BH3:F)

Loading...

Share Trading Volume for PTC Therapeutics Inc. Shares

Loading...

Compare Performance of PTC Therapeutics Inc. Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BH3:F

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To PTC Therapeutics Inc. (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NOVA:F
Novo Nordisk A/S +2.50 (+2.17%) EUR525.74B 45.80 4.49

ETFs Containing BH3

Symbol Name BH3's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About PTC Therapeutics Inc. (BH3:F) Stock

Stock Target Advisor's fundamental analysis for PTC Therapeutics Inc.'s stock is Slightly Bearish.

Unfortunately we do not have enough data on BH3:F's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on BH3:F's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on BH3:F's stock to indicate if its overvalued.

The last closing price of BH3:F's stock was EUR 23.40.

The most recent market capitalization for BH3:F is EUR 1.82B.

Unfortunately we do not have enough analyst data on BH3:F's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains PTC Therapeutics Inc.'s stock.

As per our most recent records PTC Therapeutics Inc. has 988 Employees.

PTC Therapeutics Inc.'s registered address is 100 Corporate Court, South Plainfield, NJ, United States, 07080. You can get more information about it from PTC Therapeutics Inc.'s website at https://www.ptcbio.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...